Gilbert Poon, MD
Internal Medicine · Parsippany, NJNPI 1265465900
Payments from drug & device makers
Across 679 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Welch Allyn$2K
- AstraZeneca$2K
- Amgen$1K
- Novo Nordisk$927
- AbbVie$807
- Baxter Healthcare$783
- plus $4K from 30 others
What the payments were for
- Food & beverage$9,13674%
- Education$240%
- Other$3,13325%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Welch Allyn | 1 | $2,350 |
| AstraZeneca | 113 | $1,748 |
| Amgen | 113 | $1,301 |
| Novo Nordisk | 75 | $927 |
| AbbVie(2 entities) | 84 | $807 |
| Baxter Healthcare | 1 | $783 |
| Lilly USA, LLC | 56 | $779 |
| GSK | 29 | $455 |
| Boehringer Ingelheim | 26 | $405 |
| Merck | 25 | $351 |
| Johnson & Johnson | 26 | $347 |
| Bayer | 19 | $343 |
| Novartis | 16 | $226 |
| Exact Sciences | 9 | $215 |
| Pfizer | 13 | $190 |
| Indivior Inc. | 12 | $170 |
| Kowa Pharmaceuticals America, Inc. | 10 | $148 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $127 |
| Esperion Therapeutics, Inc. | 6 | $87 |
| Amarin Pharma, Inc. | 5 | $75 |
| Almatica Pharma LLC | 5 | $66 |
| Teva Pharmaceuticals USA, Inc. | 4 | $56 |
| Althera Pharmaceuticals LLC | 4 | $48 |
| Shire North American Group Inc | 3 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Neos Therapeutics, LP | 2 | $31 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Optinose US, Inc. | 1 | $13 |
| Alkermes, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NONE$2,350
How this compares
$12,293 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $72,263 |
| FarxigaDapagliflozin Propanediol | 60 | $71,073 |
| JanuviaSitagliptin Phosphate | 87 | $68,157 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $42,145 |
| EliquisApixaban | 43 | $41,736 |
| JardianceEmpagliflozin | 39 | $36,758 |
| MounjaroTirzepatide | 26 | $27,635 |
| XareltoRivaroxaban | 40 | $25,421 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $24,445 |
| MyrbetriqMirabegron | 15 | $12,656 |
| LinzessLinaclotide | 12 | $10,875 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 162 | $9,027 |
| Atorvastatin Calcium | 728 | $7,330 |
| Valsartan | 247 | $7,280 |
| Colesevelam Hcl | 18 | $6,905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $351 | $92,602107 claims |
| Novo NordiskOzempic | $927 | $72,26367 claims |
| AstraZenecaFarxiga | $1,748 | $71,07360 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $455 | $46,61971 claims |
| PfizerEliquis | $190 | $41,73643 claims |
| Boehringer IngelheimJardiance | $405 | $36,75839 claims |
| Lilly USA, LLCMounjaro | $779 | $27,63526 claims |
| Johnson & JohnsonXarelto | $347 | $25,42140 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $12,65615 claims |
| AbbVieLinzess | $807 | $10,87512 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $15 | $2,04325 claims |
| Almatica Pharma LLCSertraline Hcl | $66 | $1,642157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Parsippany
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.